AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02525276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hormone treatment
Description: Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat
Study NCT05413512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute psychological stress
Description: Participants will undergo an acute psychological stress task that has been shown to elicit neural, cardiovascular, and psychological (feelings of stressfulness) responses.
Study NCT02525276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone treatment
Description: Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat
Study NCT05346250 — intervention group
Intervention type: BEHAVIORAL
Intervention: Non-exercise control
Description: 12 month lifestyle education
Study NCT05346250 — intervention group
Intervention type: BEHAVIORAL
Intervention: Moderate intensity exercise
Description: 12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.
Study NCT05346250 — intervention group
Intervention type: BEHAVIORAL
Intervention: Vigorous intensity exercise
Description: 6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
Study NCT04108442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.
Study NCT04108442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual
Description: Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
Study NCT04376879 — intervention group
Intervention type: OTHER
Intervention: Data monitoring for 48h within the first 24 hours of admission for COVID-19
Description: The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )
Study NCT00562120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
Study NCT00562120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra
Description: A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
Study NCT00562120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra-D
Description: A single oral dose of Allegra-D is dosed to subjects as an active comparator.
Study NCT00562120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654746
Description: A single oral dose of PF-03654746 is the investigational drug being studied.
Study NCT02698930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
Study NCT02698930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
Study NCT01266603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDIL-2
Description: 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
Study NCT01266603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recMAGE-A3 + AS15
Description: 300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
Study NCT04975724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposom Forte
Description: Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
Study NCT04975724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC
Study NCT04975724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Liposom Forte Placebo (2 ampoules of 2 ml solution for injection)
Study NCT01207492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Taken orally twice daily
Study NCT00198354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + cisplatine
Description: gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
Study NCT00198354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatine
Description: paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
Study NCT04650750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin
Description: Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect.
Study NCT04650750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar placebo 4g twice a day for two months
Study NCT01500616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
Study NCT01500616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
Study NCT01040273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT01040273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01337596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously
Study NCT01337596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT04646694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
Study NCT04646694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
Study NCT03012893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound sagittal scan
Description: Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
Study NCT03866031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implant-supported mandibular overdenture
Description: The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
Study NCT02437513 — intervention group
Intervention type: DEVICE
Intervention: NewBreez
Description: Intralaryngeal prosthesis to protect the airways
Study NCT05201742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Threshold inspiratory muscle training was performed for 6 weeks with device.
Study NCT05201742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Spirometry
Description: Incentive spirometry was performed for 6 weeks with device.
Study NCT04375969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body cryostimulation treatment
Description: The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
Study NCT04375969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connection WBC treatment and HIIT training
Description: WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions
Study NCT04375969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study
Study NCT04375969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT training group
Description: This group will do the training program without cold exposure
Study NCT04138069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLB+Aerobic Bicycling
Description: Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes
Study NCT04138069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Bicycling
Description: Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes
Study NCT04484948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT
Description: 1. Participants will perform the SHAQ.~2. BHT and 6MWT will be performed in the randomized way for each participant.~3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~4. 6MWT will be performed according to the ATS guidelines.~5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT.
Study NCT01499069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium
Description: Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months
Study NCT01613365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
Study NCT01613365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oropharyngeal and nasopharyngeal decontamination with placebo
Study NCT00940030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical bowel preparation
Description: fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
Study NCT00940030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enema
Description: fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
Study NCT00940030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enema
Description: fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
Study NCT03228420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senza HF10 Therapy
Description: Senza 10kHz Spinal Cord Stimulation
Study NCT03228420 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CMM
Description: Conventional Medical Management
Study NCT03157167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study NCT01823354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography
Description: Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
Study NCT01823354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Scales
Description: Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
Study NCT01823354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of executive functions
Description: Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing).
Study NCT01823354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical consultation
Description: open questions
Study NCT01232231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological decolonization treatment
Description: Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
Study NCT01232231 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
Study NCT00794781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201
Description: E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m\^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
Study NCT03115047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection
Description: 0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
Study NCT03115047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine Injection
Description: 0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
Study NCT04516369 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: voretigene neparvovec
Description: Voretigene neparvovec is an adeno-associated viral type 2 (AAV2) gene therapy vector driving expression of normal human retinal pigment epithelium 65 kDa protein (hRPE65) gene.
Study NCT02611960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT02611960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral tablet
Study NCT02611960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study NCT03968042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor
Description: Intramuscular injection for 2 weeks
Study NCT03968042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Intravenous injection for 2 weeks
Study NCT03968042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of vitamin B1, B6, C, E and mecobalamine
Description: Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
Study NCT03968042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination of vitamin B1, B6, C, E and mecobalamine
Description: Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
Study NCT02611960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study NCT02524093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Mental Training
Description: Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
Study NCT02524093 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: treatment as usual
Study NCT01340547 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: palifosfamide-tris
Description: palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
Study NCT01340547 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: 0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
Study NCT01722396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT03547505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R-Pilot®
Description: Glide path preparation using R-Pilot® in reciprocating manner.
Study NCT03547505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ProGlider®
Description: Glide path preparation using ProGlider® in a rotating manner.
Study NCT03547505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual preparation
Description: Glide path preparation using manual K-files numbered from 08 to 15.